Loading...

Caladrius Biosciences

DB:8NE2
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8NE2
DB
$30M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company, develops therapeutic product candidates to address diseases and conditions caused by ischemia. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
  • Caladrius Biosciences has significant price volatility in the past 3 months.
8NE2 Share Price and Events
7 Day Returns
-6.3%
DB:8NE2
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-27.3%
DB:8NE2
-10.6%
DE Biotechs
-6.2%
DE Market
8NE2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Caladrius Biosciences (8NE2) -6.3% -18% -38.9% -27.3% -57% -94.4%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 8NE2 underperformed the Biotechs industry which returned -10.6% over the past year.
  • 8NE2 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
8NE2
Industry
5yr Volatility vs Market

Value

 Is Caladrius Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Caladrius Biosciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Caladrius Biosciences.

DB:8NE2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:8NE2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:8NE2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Caladrius Biosciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:8NE2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -17.95 Analyst x1 -16.63
2020 -24.22 Analyst x1 -20.78
2021 -20.87 Analyst x1 -16.58
2022 -18.50 Analyst x1 -13.61
2023 10.39 Analyst x1 7.08
2024 14.58 Est @ 40.29% 9.20
2025 18.70 Est @ 28.27% 10.93
2026 22.41 Est @ 19.86% 12.13
2027 25.54 Est @ 13.97% 12.80
2028 28.06 Est @ 9.85% 13.03
Present value of next 10 years cash flows $-2.43
DB:8NE2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $28.06 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$363.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $363.00 ÷ (1 + 7.98%)10
$168.52
DB:8NE2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-2.43 + $168.52
$166.10
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $166.10 / 9.93
$16.72
DB:8NE2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:8NE2 represents 0.85244x of NasdaqCM:CLBS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85244x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 16.72 x 0.85244
€14.25
Value per share (EUR) From above. €14.25
Current discount Discount to share price of €2.62
= -1 x (€2.62 - €14.25) / €14.25
81.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Caladrius Biosciences is available for.
Intrinsic value
>50%
Share price is €2.62 vs Future cash flow value of €14.25
Current Discount Checks
For Caladrius Biosciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Caladrius Biosciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Caladrius Biosciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Caladrius Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Caladrius Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8NE2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.67
NasdaqCM:CLBS Share Price ** NasdaqCM (2019-04-18) in USD $3.07
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Caladrius Biosciences.

DB:8NE2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CLBS Share Price ÷ EPS (both in USD)

= 3.07 ÷ -1.67

-1.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Caladrius Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Caladrius Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Caladrius Biosciences's expected growth come at a high price?
Raw Data
DB:8NE2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
10.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Caladrius Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Caladrius Biosciences's assets?
Raw Data
DB:8NE2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.83
NasdaqCM:CLBS Share Price * NasdaqCM (2019-04-18) in USD $3.07
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:8NE2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CLBS Share Price ÷ Book Value per Share (both in USD)

= 3.07 ÷ 3.83

0.8x

* Primary Listing of Caladrius Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Caladrius Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Caladrius Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Caladrius Biosciences has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Caladrius Biosciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Caladrius Biosciences expected to grow at an attractive rate?
  • Unable to compare Caladrius Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Caladrius Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Caladrius Biosciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:8NE2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8NE2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 10.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8NE2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8NE2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 24 -6 1
2022-12-31 18 -18 2
2021-12-31 13 -16 2
2020-12-31 10 -18 1
2019-12-31 0 -25 -18 3
DB:8NE2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -20 -16
2018-09-30 -21 -17
2018-06-30 -22 -17
2018-03-31 -17 -14
2017-12-31 -21 -16
2017-09-30 -20 -18
2017-06-30 -20 -20
2017-03-31 -7 -26 -26
2016-12-31 -24 -31
2016-09-30 8 -29 -59
2016-06-30 13 -32 -64
2016-03-31 27 -33 -74

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Caladrius Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Caladrius Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8NE2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Caladrius Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8NE2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.43 0.15 -1.01 2.00
2022-12-31 -0.64 -0.41 -0.86 2.00
2021-12-31 -0.56 -0.46 -0.66 2.00
2020-12-31 -0.69 -0.69 -0.69 2.00
2019-12-31 -1.71 -1.71 -1.71 1.00
DB:8NE2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.67
2018-09-30 -1.72
2018-06-30 -1.75
2018-03-31 -1.55
2017-12-31 -1.78
2017-09-30 -2.04
2017-06-30 -2.54
2017-03-31 -3.55
2016-12-31 -4.74
2016-09-30 -9.91
2016-06-30 -11.19
2016-03-31 -13.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Caladrius Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Caladrius Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Caladrius Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Caladrius Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Caladrius Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Caladrius Biosciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Caladrius Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Caladrius Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Caladrius Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Caladrius Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8NE2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -16.17 9.39 0.09
2018-09-30 -16.54 9.77 9.04
2018-06-30 -16.51 10.65 9.82
2018-03-31 -14.40 11.94 11.68
2017-12-31 -15.99 11.75 15.84
2017-09-30 -17.67 11.37 18.09
2017-06-30 -20.18 11.20 15.97
2017-03-31 -7.49 -25.61 9.05 14.65
2016-12-31 -31.02 12.80 15.60
2016-09-30 7.56 -58.60 15.55 10.88
2016-06-30 13.45 -63.95 17.93 16.83
2016-03-31 26.80 -73.68 25.38 21.77
2015-12-31 22.49 -80.89 30.01 23.90
2015-09-30 20.20 -59.30 31.47 30.89
2015-06-30 18.43 -64.90 34.22 33.04
2015-03-31 17.06 -60.38 32.92 31.24
2014-12-31 17.94 -54.87 30.81 29.19
2014-09-30 16.74 -55.80 30.24 24.32
2014-06-30 16.33 -47.89 27.90 20.34
2014-03-31 16.20 -43.86 24.78 18.52
2013-12-31 14.67 -38.98 21.61 16.92
2013-09-30 13.34 -39.01 20.90 14.58
2013-06-30 14.07 -39.51 21.29 12.92
2013-03-31 13.08 -38.17 21.70 11.67
2012-12-31 14.33 -37.35 22.32 10.45
2012-09-30 15.79 -32.49 23.49 9.55
2012-06-30 13.53 -29.77 23.52 9.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Caladrius Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Caladrius Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Caladrius Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Caladrius Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Caladrius Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Caladrius Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Caladrius Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Caladrius Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Caladrius Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Caladrius Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Caladrius Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Caladrius Biosciences Company Filings, last reported 3 months ago.

DB:8NE2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 37.45 0.00 43.05
2018-09-30 40.81 0.00 46.15
2018-06-30 43.47 0.02 50.32
2018-03-31 45.32 0.09 48.58
2017-12-31 50.19 0.16 55.08
2017-09-30 52.98 0.36 59.45
2017-06-30 54.04 0.60 59.37
2017-03-31 17.42 6.12 12.00
2016-12-31 23.47 6.37 7.08
2016-09-30 29.39 6.62 18.61
2016-06-30 25.04 9.99 17.70
2016-03-31 32.58 13.24 25.43
2015-12-31 23.28 16.78 20.32
2015-09-30 55.00 16.83 29.39
2015-06-30 65.95 17.14 39.22
2015-03-31 49.97 16.72 19.13
2014-12-31 58.07 16.64 26.25
2014-09-30 62.06 16.95 32.81
2014-06-30 77.30 4.94 33.79
2014-03-31 59.07 4.89 41.36
2013-12-31 62.03 4.15 46.13
2013-09-30 35.13 4.04 16.95
2013-06-30 32.99 4.18 14.72
2013-03-31 29.00 3.92 9.25
2012-12-31 32.82 3.81 13.74
2012-09-30 56.43 3.68 7.89
2012-06-30 55.43 3.75 2.12
  • Caladrius Biosciences has no debt.
  • Caladrius Biosciences has no debt compared to 5 years ago when it was 6.7%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Caladrius Biosciences has sufficient cash runway for 2.1 years based on current free cash flow.
  • Caladrius Biosciences has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of -26.7% each year.
X
Financial health checks
We assess Caladrius Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Caladrius Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Caladrius Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Caladrius Biosciences dividends.
If you bought €2,000 of Caladrius Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Caladrius Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Caladrius Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8NE2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8NE2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Caladrius Biosciences has not reported any payouts.
  • Unable to verify if Caladrius Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Caladrius Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Caladrius Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Caladrius Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Caladrius Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Caladrius Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Caladrius Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dave Mazzo
COMPENSATION $1,487,772
AGE 61
TENURE AS CEO 4.3 years
CEO Bio

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. has been the Chief Executive Officer of Caladrius Biosciences, Inc. (formerly Neostem, Inc.) since January 5, 2015 and also its President since March 29, 2017. Dr. Mazzo serves as Director at EyePoint Pharmaceuticals, Inc. since 2018. Dr. Mazzo served as Non-Executive Chairman at EyePoint Pharmaceuticals, Inc. until September 10, 2018. Dr. Mazzo served as the President and Chief Executive Officer of Chugai U.S.A., Inc. He served as the Chief Executive Officer of Regado Biosciences, Inc. from August 2008 to October 10, 2014. He served as the President at Regado Biosciences, Inc. since August 2008. He served as the President and Chief Executive Officer of Chugai Pharma USA LLC, the U.S. subsidiary of Chugai Pharmaceutical Ltd. of Japan, since April 2003. He served as the President and Chief Executive Officer of AEterna Zentaris Inc. from April 9, 2007 to April 2008. Prior to Chugai, Dr. Mazzo served in management positions in several international pharmaceutical companies, served as Senior Vice President of Global Development Operations at the Schering-Plough Research Institute and as Senior Vice President and Global Head Pharmaceutical Development at Hoechst Marion Roussel. He is a Pharmaceutical Executive and Strategic Leader with broad technical and managerial experience gained from working in a variety of multicultural and multilingual environments in the USA, Canada, Europe and Asia. He has spent more than 25 years in the pharmaceutical industry and is recognized for his leadership and strong strategic, scientific and regulatory expertise. He has broad experience working in a variety of multi-cultural environments in the USA, Europe and Asia where he amassed a track record of successful global product development, registration and launch. He has occupied positions of increasing responsibility with Merck, Baxter, Rhone-Poulenc Rorer, Hoechst Marion Roussel and Schering-Plough, where he was involved with the launch of Clarinex (TM), Nasonex(TM), Asmanex Twisthaler(TM), PEG-Intron(TM), PEG-Intron Redipen(TM) and Zetia(TM). Through his multiple assignments and many accomplishments, he has acquired a thorough understanding of the drug development process from Discovery to Manufacturing and Launch. In his previous position as the Senior Vice President of Development Operations for the Schering-Plough Research Institute, he led an organization of approximately 1,100 employees spanning three countries. Dr. Mazzo has been the Non-Executive Chairman of Psivida Corp. since January 24, 2007. He serves as the Non-Executive Chairman of Psivida US, Inc. He has been a Director of Caladrius Biosciences, Inc. since January 5, 2015. He has been a Non-Executive Director of Psivida Ltd. of Perth, Australia since July 25, 2005. He has been a Non-Executive Director of Psivida Corp. since July 25, 2005. He served as a Director of Regado Biosciences, Inc. from August 2008 to October 10, 2014. He served as a Director of AEterna Zentaris Inc. from August 14, 2007 to April 2008. He served as a Director of Avanir Pharmaceuticals, Inc. from July 25, 2005 to January 13, 2015. Dr. Mazzo holds Bachelor of Arts degree in the Honors Program (Interdisciplinary Humanities) and a Bachelor of Science degree in Chemistry from Villanova University. In addition, Dr. Mazzo received his Master of Science degree in Chemistry and his Ph.D. Degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.

CEO Compensation
  • Dave's compensation has been consistent with company performance over the past year.
  • Insufficient data for Dave to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Caladrius Biosciences management team in years:

3.9
Average Tenure
56.5
Average Age
  • The tenure for the Caladrius Biosciences management team is about average.
Management Team

Dave Mazzo

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
61
TENURE
4.3 yrs

Doug Losordo

TITLE
Executive VP
COMPENSATION
$760K
AGE
60
TENURE
5.7 yrs

Joe Talamo

TITLE
CFO & Senior VP
COMPENSATION
$432K
AGE
49
TENURE
3.5 yrs

John Menditto

TITLE
Executive Director of Investor Relations & Corporate Communications
TENURE
1.3 yrs

Todd Girolamo

TITLE
General Counsel & Corporate Secretary
TENURE
3.5 yrs

Eric Powers

TITLE
Director of Communications & Marketing

Ian Zhang

TITLE
President of NeoStem (China)
AGE
53
TENURE
8.6 yrs
Board of Directors Tenure

Average tenure and age of the Caladrius Biosciences board of directors in years:

4.3
Average Tenure
63
Average Age
  • The tenure for the Caladrius Biosciences board of directors is about average.
Board of Directors

Greg Brown

TITLE
Chairman of the Board
COMPENSATION
$45K
AGE
64
TENURE
2.2 yrs

Dave Mazzo

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
61
TENURE
4.3 yrs

Ric Myers

TITLE
Lead Director
COMPENSATION
$102K
AGE
71

Steve Klosk

TITLE
Independent Director
COMPENSATION
$86K
AGE
61
TENURE
4.8 yrs

Peter Traber

TITLE
Independent Director
COMPENSATION
$79K
AGE
63
TENURE
4.3 yrs

David Horwitz

TITLE
Immune Modulation Program Advisor

Robert Korngold

TITLE
Immune Modulation Program Advisor

Robert Negrin

TITLE
Immune Modulation Program Advisor

David Peritt

TITLE
Immune Modulation Program Advisor

Noel Warner

TITLE
Immune Modulation Program Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Caladrius Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Caladrius Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company, develops therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 that is in Phase II clinical trial for the treatment of critical limb ischemia; CLBS14-CMD, which is in Phase II clinical study to treat coronary microvascular dysfunction; and CLBS14-NORDA that is in Phase III clinical trial for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.

Details
Name: Caladrius Biosciences, Inc.
8NE2
Exchange: DB
Founded: 1980
$27,115,171
9,932,865
Website: http://www.caladrius.com
Address: Caladrius Biosciences, Inc.
110 Allen Road,
2nd Floor,
Basking Ridge,
New Jersey, 07920,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CLBS Common Stock Nasdaq Capital Market US USD 09. Apr 1981
DB 8NE2 Common Stock Deutsche Boerse AG DE EUR 09. Apr 1981
LSE 0HS8 Common Stock London Stock Exchange GB USD 09. Apr 1981
Number of employees
Current staff
Staff numbers
25
Caladrius Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:44
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.